Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
GLP1R 2740 ISRADIPINE CHEMBL1648 agonist GuideToPharmacologyInteractions
GLP1R 2740 EXENATIDE CHEMBL414357 agonist, binder TdgClinicalTrial, ChemblInteractions, TEND, DrugBank, TTD 17379930, 16627399, 11752352, 17292977, 16341288, 15331551, 16534527, 20649595, 17353295, 15700891, 15495988, 16722815
GLP1R 2740 SEMAGLUTIDE CHEMBL2108724 agonist ChemblInteractions
GLP1R 2740 LIXISENATIDE CHEMBL2108336 agonist GuideToPharmacologyInteractions, ChemblInteractions
GLP1R 2740 PALIVIZUMAB CHEMBL1201586 agonist TdgClinicalTrial, TTD
GLP1R 2740 CHEMBL1210015 CHEMBL1210015 agonist TdgClinicalTrial, GuideToPharmacologyInteractions
GLP1R 2740 TASPOGLUTIDE CHEMBL2107860 agonist TdgClinicalTrial, ChemblInteractions
GLP1R 2740 GLUCAGON CHEMBL266481 agonist GuideToPharmacologyInteractions, DrugBank 17498508, 17475961, 12529935, 17534934
GLP1R 2740 LIRAGLUTIDE CHEMBL1201866 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank, TTD 14678021, 18333889
GLP1R 2740 DULAGLUTIDE CHEMBL2108027 agonist ChemblInteractions, DrugBank 25367716
GLP1R 2740 ALBIGLUTIDE CHEMBL2107841 agonist TdgClinicalTrial, ChemblInteractions, DrugBank 25136065

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
GLP1R rs6923761 AA sitagliptin efficacy yes as measured by reduction in glycated hemoglobin over 6 months. Genotype AA is associated with decreased clinical benefit to sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to genotypes AG + GG. 32308134 1451128780
GLP1R rs6923761 AA sitagliptin efficacy yes The main study outcome was reduction of HbA1c after 6-months of uninterrupted treatment with glistens. The genetic association was significant with an additive genetic model. Genotype AA is associated with decreased response to sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to genotype GG. 27160388 1448099032
GLP1R rs10305420 CT + TT liraglutide efficacy yes Strong responders (response) were classified as subjects who lost 5 % or more of their initial body weight. Poor responders lost less than 5 % of initial weight. All the patients were given a dose of liraglutide of 0.6 mg/day (injected) s.c. which increased to 1.2 mg/day after 1 for 12 weeks. Additionally, patients were recommended to try an energy restricted diet (500–800 kcal/day reduction made up of 50 % carbohydrates, 20 % proteins, and 30 % of fat with increased consumption of fiber, whole grain breads, cereals, fruits, and vegetables) and at least 30 min of moderate intensity physical activity daily. Genotypes CT + TT are associated with decreased response to liraglutide in women with Obesity and Polycystic Ovary Syndrome as compared to genotype CC. 25991051 1444843016
GLP1R rs10305420 T exenatide efficacy yes as measured by weight loss and HbA1c reduction. Allele T is associated with decreased response to exenatide in people with Diabetes Mellitus, Type 2 as compared to allele C. 30883264 1450375492
GLP1R rs3765467 A exenatide efficacy no as measured by weight loss and HbA1c reduction, but this association was only marginal. Alleles complemented, paper states "mutant T allele of rs3765467, which causes an amino acid change from Arg to Gln, was marginally associated with HbA1c reduction". Allele A is associated with decreased response to exenatide in people with Diabetes Mellitus, Type 2 as compared to allele G. 30883264 1450375507
GLP1R rs6923761 AA + AG liraglutide efficacy no Strong responders (response) were classified as subjects who lost 5 % or more of their initial body weight. Poor responders lost less than 5 % of initial weight. All the patients were given a dose of liraglutide of 0.6 mg/day (injected) s.c. which increased to 1.2 mg/day after 1 for 12 weeks. Additionally, patients were recommended to try an energy restricted diet (500–800 kcal/day reduction made up of 50 % carbohydrates, 20 % proteins, and 30 % of fat with increased consumption of fiber, whole grain breads, cereals, fruits, and vegetables) and at least 30 min of moderate intensity physical activity daily. Genotypes AA + AG are associated with increased response to liraglutide in women with Obesity and Polycystic Ovary Syndrome as compared to genotype GG. 25991051 1444842903